NLST肺癌筛查低剂量CT全队列器官剂量评估
本研究回顾性纳入25,051例NLST低剂量CT肺癌筛查参与者,利用NCI剂量计算系统与性别、体型特异性体模估算器官吸收剂量和有效剂量。结果显示中位每次检查有效剂量为2.07 mSv,参与者中位累计有效剂量为5.94 mSv,甲状腺剂量不确定性最高。
要点
- 低剂量肺癌筛查CT中位单次有效剂量为2.07 mSv,累计中位为5.94 mSv。
- 乳腺、肺、心壁单次中位剂量接近3.9 mGy,需关注重复筛查的乳腺辐射。
- 甲状腺剂量因扫描范围差异变异性最大,平均变异系数达21.1%。
核心结论
- NLST低剂量CT肺癌筛查队列中位单次有效剂量为2.07 mSv,中位累计有效剂量为5.94 mSv。
- 肺、乳腺、心壁的单次中位器官剂量接近,约为3.9 mGy,累计中位剂量约为11.3-11.4 mGy。
- 甲状腺剂量受扫描范围影响最大,平均变异系数为21.1%,而扫描野内器官剂量不确定性较低。
研究设计与样本
- 回顾性剂量学研究,纳入NLST中Lung Screening Study和ACRIN部分共25,051例低剂量CT筛查参与者。
- 排除任何一次检查缺少有效管电流时间输入记录的参与者,最终纳入69,601次研究级筛查检查。
- 采用NCI CT剂量计算系统,结合年龄、性别、身高、体重及性别和体型特异性成年体模计算器官剂量。
- 通过50次随机模拟评估扫描范围相关的剂量不确定性。
诊断标准与关键数值
- 研究级容积CT剂量指数中位数为3.30 mGy。
- 研究级肺、乳腺、心壁、活性骨髓中位剂量分别为3.93、3.94、3.94、1.26 mGy,有效剂量为2.07 mSv。
- 参与者累计肺、乳腺、心壁、活性骨髓中位剂量分别为11.30、11.39、11.41、3.63 mGy,有效剂量为5.94 mSv。
- 参与者平均接受2.78次研究级筛查检查。
- 甲状腺剂量平均变异系数为21.1%,为扫描范围相关剂量不确定性最高的器官。
临床应用与阅片要点
- 报告低剂量肺癌筛查CT辐射剂量时可参考单次有效剂量约2 mSv的量级进行患者沟通。
- 对需要多次年度筛查者,应关注乳腺和心壁累计剂量约11 mGy的长期影响。
- 甲状腺剂量高度依赖扫描范围,优化扫描起始位置可减少甲状腺受照。
局限性
- 本研究为回顾性剂量学研究,剂量估算依赖元数据质量和体模近似,不代表个体实际解剖剂量。
- 排除缺少有效管电流时间输入的检查可能导致选择偏倚。
- 扫描范围相关剂量不确定性在甲状腺等边界器官最为明显。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Organ-specific dose estimates are needed to characterize radiation exposure from repeated low-dose computed tomography (CT) lung cancer screening in the National Lung Screening Trial (NLST). The objective was to estimate study-level doses and participant-level cumulative doses in the NLST CT screening cohort.
MATERIALS AND METHODS: This retrospective dosimetry study included 25,051 NLST CT screening participants from the Lung Screening Study and American College of Radiology Imaging Network components after excluding participants with any examination lacking a valid manufacturer-appropriate tube current-time input. Image-series metadata were linked with age, sex, height, and weight, and then valid records were grouped into 69,601 study-level screening examinations. Organ absorbed doses and effective dose were calculated using the National Cancer Institute dosimetry system for Computed Tomography with sex- and body-size-specific adult phantoms. Scan-range-related dose uncertainty was assessed with 50 stochastic simulations.
RESULTS: Participants underwent a mean of 2.78 study-level screening examinations; the median study-level volume CT dose index was 3.30 mGy. Median (interquartile range) study-level lung, breast, heart wall, active marrow, and effective doses were 3.93 (3.13-4.96), 3.94 (3.14-5.04), 3.94 (3.14-5.01), and 1.26 (0.99-1.60) mGy, and 2.07 (1.65-2.59) mSv, respectively. Corresponding cumulative participant-level doses were 11.30 (8.89-14.50), 11.39 (9.01-14.75), 11.41 (8.93-14.66), and 3.63 (2.79-4.66) mGy, and 5.94 (4.69-7.64) mSv. Scan-range-related dose uncertainty was greatest for thyroid dose (mean coefficient of variation, 21.1%) and low for in-field organs.
CONCLUSION: Using NLST low-dose CT screening data, we estimated participant-level cumulative organ and effective doses and characterized variation across organs and body-size groups.
引用
- Academic Radiology:Full-Cohort Organ Dose Assessment from Low-Dose CT Lung Cancer Screening in the National Lung Screening Trial
- Lee, Moroz, Hwang, et al. Full-Cohort Organ Dose Assessment from Low-Dose CT Lung Cancer Screening in the National Lung Screening Trial. Acad Radiol. 2026. PMID: 42907269. doi:10.1016/j.acra.2026.09.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。